# Diabetes Mellitus, Type 1 FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/diabetes-mellitus-type-1

> 6 upcoming FDA catalysts in diabetes Mellitus, Type 1: Awiqli Flextouch (insulin icodec, NVO) on Jan to Apr 2027 (topline data readout); Awiqli Flextouch (insulin icodec, NVO) on January 2027 (primary completion); cadisegliatin (VTVT) on April 2027 (primary completion); cadisegliatin (VTVT) on Apr to Jul 2027 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 20, 2025 | [Dasiglucagon primary completion](https://sec-api.dev/pdufa/dasiglucagon) | NVO | Diabetes Mellitus, Type 1 | completed | "NCT06588504 (Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-20 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-11-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588504)) |
| November 16, 2026 | [Dasiglucagon topline data readout](https://sec-api.dev/pdufa/dasiglucagon) | NVO | Diabetes Mellitus, Type 1 | completed | "NCT06588504 (Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-20 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-11-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588504?tab=results)) |
| Jan to Apr 2027 | [Awiqli Flextouch (insulin icodec) topline data readout](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes Mellitus, Type 1 | scheduled | "NCT07076199 (A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076199)) |
| January 2027 | [Awiqli Flextouch (insulin icodec) primary completion](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes Mellitus, Type 1 | scheduled | "NCT07076199 (A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076199)) |
| April 2027 | [Cadisegliatin primary completion](https://sec-api.dev/pdufa/cadisegliatin) | VTVT | Diabetes Mellitus, Type 1 | scheduled | "NCT06334133 (Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor vTv Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06334133)) |
| Apr to Jul 2027 | [Cadisegliatin topline data readout](https://sec-api.dev/pdufa/cadisegliatin) | VTVT | Diabetes Mellitus, Type 1 | scheduled | "NCT06334133 (Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor vTv Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06334133)) |
| July 2028 | [OLUMIANT® (baricitinib) primary completion](https://sec-api.dev/pdufa/baricitinib) | LLY | Diabetes Mellitus, Type 1 | scheduled | "NCT07222332 (A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222332)) |
| Jul to Oct 2028 | [OLUMIANT® (baricitinib) topline data readout](https://sec-api.dev/pdufa/baricitinib) | LLY | Diabetes Mellitus, Type 1 | scheduled | "NCT07222332 (A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222332)) |

## Drugs

- [Dasiglucagon](https://sec-api.dev/pdufa/dasiglucagon) (NVO)
- [Awiqli Flextouch (insulin icodec)](https://sec-api.dev/pdufa/insulin-icodec) (NVO)
- [Cadisegliatin](https://sec-api.dev/pdufa/cadisegliatin) (VTVT)
- [OLUMIANT® (baricitinib)](https://sec-api.dev/pdufa/baricitinib) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/diabetes-mellitus-type-1.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Diabetes Mellitus, Type 1 FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/diabetes-mellitus-type-1

```bibtex
@misc{secapidev_indications_diabetes_mellitus_type_1_20261116,
  title        = {Diabetes Mellitus, Type 1 FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/diabetes-mellitus-type-1}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_diabetes_mellitus_type_1_20261116","title":"Diabetes Mellitus, Type 1 FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/diabetes-mellitus-type-1","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
